Companies - Pharming


Price: Price

-

Change

-

Change %

-

Open

-

High

-

Low

-

Volume

-
Profile: Profile

Pharming is an innovative biotechnology company that has the mission to create value for all shareholders through the development of therapeutic products for humans. Pharming's goal is the development and commercialization of therapeutic proteins for difficult to treat or non-treatable diseases, thus helping patients and add value for shareholders. The developed applications can be applied in the case of genetic anomalies or use in resolving tissue damage after surgery. The current focus of Pharming is on product innovation. Future growth of the company is pursued through licensing products, its technology and strategic transactions.

Site

http://www.pharming.com

Industry

Biotechnology

Description

Companies in the biotechnology industry are performing research and development activities for the purpose of discovering new drugs and diagnostics. The turnover of these companies comes from sales of these products or the sale of licenses of drugs and diagnostic to other companies.
Key figures (2020): The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings

24,496

Price to Earnings (3 years)

25,767

Price to Earnings (5 years)

-1.237,516

Price to earnings growth

-

Price/cashflow

24,496

Price/net cashflow

10,600

Price/book value

5,418

Price to sales

4,321

Ratios for dividend

Dividend yield

-

Pay out

-

Valuation ratios

Market value/PE

5,418

Market value/turnover

4,321

Enterprise value/turnover

3,511

Return ratios

Return on private equity

22,12%

Return on total equity

9,70%

Profit margin

17,64%

Risk ratios

Solvability

0,438

Solvability

1,781

Current ratio

3,425

Debt to Equity

1,281

Value invest ratios

Grahams Number

€ 0,04

Grahams Value

€ 0,04

Grahams Product

132,716

Grahams Product (3 years)

139,604
2020: Profit and loss

Net profit (x 1 mln)

€ 33,04

Turnover (x 1 mln)

€ 187,29

Cashflow(x 1 mln)

€ 33,04

Net cashflow(x 1 mln)

€ 76,35

Balance

Private equity (x 1 mln)

€ 149,38

Foreign equity (x 1 mln)

€ 191,38

Current assets (x 1 mln)

€ 214,34

Current liabilities (x 1 mln)

€ 62,58

Working capital (x 1 mln)

€ 151,76

Balance total (x 1 mln)

€ 340,76

Share

Outstanding shares (x 1 mln)

636,270

Price year-end

€ 1,27

Dividend per share

-

Earnings per share

€ 0,05

Cashflow per share

€ 0,05

Net cashflow per share

€ 0,12

Book value per share

€ 0,23

Stockmarket value (x 1 mln)

€ 809,34
History: Year

2020

2019

2018

2017

2016

Net profit (x 1 mln)

€ 33,04

€ 36,20

€ 24,99

€ -79,96

€ -17,54

Turnover (x 1 mln)

€ 187,29

€ 169,02

€ 135,13

€ 89,62

€ 16,21

Price year-end

€ 1,27

€ 1,57

€ 0,76

€ 1,13

€ 0,22

Year high

€ 1,60

€ 1,64

€ 1,62

€ 1,38

€ 0,32

Year low

€ 0,75

€ 0,71

€ 0,64

€ 0,22

€ 0,15

Outstanding shares (x 1 mln)

636,270

631,320

621,500

579,010

407,687

Price to Earnings

24,496

27,337

18,839

-8,197

-5,044

Earnings per share

€ 0,05

€ 0,06

€ 0,04

€ -0,14

€ -0,04

Dividends

-

-

-

-

-

Dividend yield

-

-

-

-

-

Pay out

-

-

-

-

-

Private equity (x 1 mln)

€ 149,38

€ 104,68

€ 61,75

€ 18,80

€ 27,47

PE per share

€ 0,23

€ 0,17

€ 0,10

€ 0,03

€ 0,07

Balance total (x 1 mln)

€ 340,76

€ 228,21

€ 214,57

€ 166,19

€ 126,78

Stockmarket value (x 1 mln)

€ 809,34

€ 989,59

€ 470,79

€ 655,44

€ 88,47
Company analysis: Analysis of profit indicators

Average profit per share (10 years)

€ -0,10

Standard deviation average profit

€ 0,14 (-142,98%)

Average annual growth rate

-8,48%

Compound annual growth percentage

8,57%

Pharming

Shares

Compare

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok Decline